Merck pledges nearly $2 billion to acquire an oral lipid-lowering drug from a Chinese biotech, aiming to expand its cardiovascular portfolio and address global cholesterol management needs.
Browsing: investment
Merck pledges nearly $2 billion to acquire an oral lipid-lowering drug from a Chinese biotech, aiming to expand its cardiovascular portfolio and address global cholesterol management needs.